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Nitric oxide modulates vascular endothelial growth factor and lar hyalinosis [1]. While acute nephrotoxicity results from
receptors in chronic cyclosporine nephrotoxicity. renal vasoconstriction, the mechanisms leading to chronic
Background. Vascular endothelial growth factor (VEGF) is nephrotoxicity are unclear [2]. In order to study chronicinvolved in angiogenesis, wound healing, and inflammation and
CsA nephrotoxicity, a reproducible animal model wasexerts its effect via tyrosine kinase receptors, fms-like tyrosine
kinase (Flt-1) and fetal liver kinase (Flk-1 or KDR). We have developed with features that resemble the renal lesion
previously shown that VEGF is up-regulated in a model of chronic described in patients on long-term CsA therapy. Our
cyclosporine (CsA) nephrotoxicity and that l-arginine (l-Arg) previous studies have shown that transforming growthimproved while N-nitro-l-arginine-methyl ester (L-NAME)
factor-1 (TGF-1) is involved in the fibrosis of thisworsened fibrosis. We examined the role of nitric oxide modu-
lation on VEGF in this model. model and that apoptosis plays a central role [3, 4]. More
Methods. Pair-fed salt-depleted rats were administered CsA, recently, we have demonstrated an up-regulated expres-
CsAL-NAME, CsA l-Arg, vehicle (VH), VHL-NAME sion of vascular endothelial growth factor (VEGF) inor VH l-Arg and were sacrificed at 7 or 28 days. Physiologic
this model [5].and histologic changes were studied in addition to the mRNA
expression of VEGF and its receptors Flt-1 and KDR/Flk-1 VEGF is an endothelial cell mitogen that increases
by Northern blot and the protein expression of VEGF by angiogenesis and vascular permeability [6]. VEGF is che-
Western blot and immunohistochemical staining. motactic for monocytes and plays a role in wound heal-Results. While L-NAME worsened renal function and his-
ing, inflammation, and tissue remodeling [7]. Hypoxiatology, l-Arg had the opposite beneficial effect in CsA-treated
rats. VEGF mRNA and protein expressions increased with and hypoglycemia are major stimulators of VEGF ex-
CsA, further increased with L-NAME and became significantly pression. In addition, VEGF production is enhanced by
reduced with L-Arg. Flt-1 expression was similar in all groups. growth factors, including TGF-, basic fibroblast growthOn the other hand, KDR/Flk-1 mRNA expression was modu-
factor, and platelet-derived growth factor, and by cyto-lated in a fashion similar to VEGF. Also, nitric oxide modula-
kines, among them interleukin (IL)-1 and IL-6 [6, 7].tion did not have an effect on VH-treated rats.
Conclusions. VEGF expression in chronic CsA nephrotoxic- Recently, nitric oxide has drawn a great deal of attention
ity is increased by nitric oxide blockade and decreased by nitric as a regulator of the VEGF gene [8]. There is a consider-oxide enhancement. Moreover, VEGF probably exerted its
able body of evidence that nitric oxide down-regulateseffect via the KDR/Flk-1 receptor. The actions of VEGF in
the expression of the VEGF gene in the setting of hyp-this model remain speculative, but it is probable that VEGF
plays a role, either independently or through nitric oxide, in oxia [9–12]. In contrast, other studies reported that nitric
CsA-induced fibrosis. oxide induces VEGF gene transcription [13]. Moreover,
VEGF is also capable of inducing nitric oxide synthesis
through a number of complex signaling pathways [14].The clinical use of cyclosporine (CsA) is limited by
VEGF exerts much of its action by binding selectivelychronic nephrotoxicity; a histologic lesion characterized
and with high affinity to two tyrosine kinase receptorsby striped tubulointerstitial fibrosis and afferent arterio-
designated fms-like tyrosine kinase (Flt-1), also known
as VEGFR-1, and fetal liver kinase-1 (Flk-1), also known
Key words: chronic nephrotoxicity, cyclosporine, fibrosis, Flt1-1, KDR/
as KDR or VEGFR-2 [15]. The known biological re-Flk-1, l-Arginine, L-NAME, nitric oxide, rats, vascular endothelial
growth factor. sponses of VEGF on endothelial cells are reported to
be mediated mostly by the activation of KDR/Flk-1.
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phosphorylation (MAP) kinase and phospholipase C separate groups received a weight-based identical vol-
[16]. Until recently, most studies described VEGF recep- ume of vehicle olive oil as control. Four additional groups
tors’ expression as being specific to endothelial cells. received L-NAME (Sigma) and were treated with vehi-
However, there are now several reports of nonendothe- cle or CsA for 7 or 28 days. L-NAME was dissolved in
lial cells expressing VEGF receptors [17]. VEGF is con- distilled water at a concentration of 5 mg/100 mL. The
stitutively expressed on glomerular visceral epithelial rats were allowed free access to L-NAME solution in
and tubular cells, but its function is not fully delineated standard drinking bottles. The average daily intake for
[6, 7, 16, 17]. Flt-1 and KDR/Flk-1 are present, not only the rats was 23 mL (3.5 mg/kg of L-NAME). The chosen
on renal endothelial cells, but also on human mesangial doses were based on previous experiments done in the
and rat renal tubular epithelial cells [18, 19]. VEGF plays same model [25].
a role in renal endothelial development, in enhancing The experimental groups were group 1, CsA (7 days);
endothelial cell permeability and in postinjury glomeru- group 2, CsA  L-NAME (7 days); group 3, CsA 
lar regeneration. Of note is that VEGF is increased in l-Arg (7 days); group 4, vehicle (7 days); group 5,
conditions associated with macrophage infiltration and vehicle  L-NAME (7 days), group 6, vehicle  l-Arg
that both chronic renal allograft rejection and chronic (7 days); group 7, CsA (28 days); group 8, CsA 
CsA nephrotoxicity show a heavy monocytic infiltration
L-NAME (28 days); group 9, CsA  l-Arg (28 days);
[5, 20].
group 10, vehicle (28 days); group 11, vehicle L-NAMEIn the kidney, nitric oxide functions as a vasoactive
(28 days); and group 12, vehicle  l-Arg (28 days).factor important in maintaining vascular tone [21]. In
Systolic blood pressure was measured by tail plethys-addition, nitric oxide prevents glomerular thrombosis
mography (Natsume Seisakusyo, Tokyo, Japan) and 24-and ischemia, lessens mesangial cell proliferation, de-
hour urine samples were collected in metabolic cagescreases extracellular matrix (ECM) protein synthesis,
(Nalge, Rochester, NY, USA). The following day, ratsand decreases interstitial macrophage infiltration [22].
were anesthetized with ketamine, the abdomen wasDietary l-arginine (l-Arg) supplementation was shown
opened through a midline incision, and the aorta wasto be beneficial in a number of experimental renal dis-
cannulated below the renal arteries with an 18-gaugeeases presumably because it increases nitric oxide pro-
needle. The kidneys were perfused with 20 mL coldduction [23]. In contrast, N-nitro-l-arginine-methyl ester
heparinized saline solution. The left kidney was removed(L-NAME), a potent competitive inhibitor of nitric oxide
and processed for light microscopy and protein analysis.biosynthesis, was shown to worsen kidney disease. We
After removing the right kidney, the cortex was dissectedhave previously shown that nitric oxide maintains a pro-
tective function in chronic CsA nephrotoxicity by de- from the medulla, and the cortex was processed for RNA
creasing fibrosis and the expression of TGF-1 and ECM extraction. After the experiment, the animals were eu-
proteins [24]. These data, together with the recent find- thanized by deep anesthesia with ketamine.
ings that nitric oxide has a direct effect on VEGF biosyn-
Functional studiesthesis, prompted us to investigate whether nitric oxide
regulates the production of VEGF and the expression Blood was collected from the jugular vein in plastic
of its receptors Flt-1 and KDR/Flk-1 in a model of syringes transferred to metal-free tubes and chilled on
chronic CsA nephrotoxicity. ice. Plasma was harvested immediately by centrifugation
at 4C and stored at 70C until determined. Urinary
and plasma creatinine was measured by a Cobas auto-METHODS
analyzer (Roche Diagnostics, Division of Hoffman-LaExperimental design
Roche, Inc., Nutley, NJ, USA). Creatinine clearance was
Adult male Sprague-Dawley rats (Charles River, Wil-
calculated using a standard formula. CsA blood levelmington, MA, USA) weighing 200 to 250 g were housed
was measured by a monoclonal radioimmunoassay forin a temperature- and light-controlled environment and
CsA (Incstar Co., Stillwater, MN, USA). Urinary excre-received low-salt diet (0.05% sodium, Teklad Premier,
tion of the stable nitric oxide metabolites, NO2 and NO3,WI, USA) with water ad libitum. Animals were pair-fed
was determined. Urinary NO2 was assayed by the Griessand weighed daily. After 7 or 28 days on low-salt diet,
reagent. Urinary NO3 was estimated by reduction to NO2weight-matched pairs were randomized into six groups
using nitrate reductase from Aspergillus species (Boeh-of five to six rats each. Four groups were started on
ringer Mannheim Biochemicals, Indianapolis, IN, USA).l-Arg (Sigma Chemical, St. Louis, MO, USA) at a dose
The NO3 reduction was 95% to 100% effective. Urinaryof 1.7 g/kg/day added in powder form to low-salt diet.
NO3 excretion was considered the difference betweenAfter 5 days of l-Arg supplementation, CsA (Novartis,
total NO2 (after reduction) minus initial NO2 values. TheEast Hanover, NJ, USA) at a dose of 7.5 mg/kg/day was
administered subcutaneously to two groups while two results are expressed in mol per 24 hours of urine
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Morphology cules, CA, USA). The density of bands for the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA wasTissue samples were fixed in 10% buffered formalin
used to control for differences in the total amount ofand embedded in paraffin. Sections 2 to 4  thick were
RNA loaded onto each gel line. Equal loading was en-stained with periodic acid-Schiff’s (PAS) reagent and
sured by the ethidium bromide gel inspection. For quanti-trichrome stain. Tubulointerstitial fibrosis consisted of
tative purposes, values were divided by the GAPDH bandmatrix expansion with tubular distortion and collapse
density in the same lane. The VEGF cDNA probe usedand basement membranes thickening. Arteriolopathy
was a 384 bp NotI-EcoRI murine cDNA fragment of clonewas characterized by eosinophilic granular transforma-
pT7T3D-Pac (American Type Culture Collection, Rock-tion of afferent arterioles and progressed to hyalinization
ville, MD, USA). The rat GAPDH cDNA probe (plas-and destruction of the afferent arterioles and terminal
mid pBluescript KS II) was a gift from J.M. Blanchard.portions of interlobular arteries. A minimum of 20 fields
Flt-1 and KDR/Flk-1 cDNA probes were derived fromat 100 magnification were assessed and graded in each
rat reverse transcription-polymerase chain reaction (RT-biopsy by an observer masked to treatment groups using
PCR) products. For Flt-1, sense and antisense primers werea color image analyzer (Mustek Pentagon 800 SP, MacIn-
located in the extracellular region: sense 5-AGCCCACtosh Power PC 7100, NIH Image v. 1.5).
CTCTCTATCCGCTGG and antisense 5-GGCGCTTCTubulointerstitial fibrosis was estimated by counting
CGAATCTCTA. The primers for KDR/Flk-1 were sensethe percentage of injured areas per field and scored semi-
5-AGCTTGGCTCACAGGCAACATCGG (located inquantitatively as follows: 0  normal interstitium; 0.5 
the 6 IgG-like domain) and antisense 5-TGGCCCCGC	5% of areas injured; 1 5% to15%; 1.5 16% to 25%,
TTAACGGTCCGT (located between trans-membrane2  26% to 35%; 2.5  36% to 45%; and 3  
45%.
region and intracellular domain). For RT-PCR, 5 gArteriolar hyalinosis was assessed by counting the per-
total RNA were combined with 2 L random primerscentage of afferent arterioles available for examination
(Gibco) and 2 L of Moloney murine leukemia virus RTwith a minimum of 100 glomeruli per biopsy and scored
per manufacturer’s instructions. RT product, 1 to 2 L,semiquantitatively as follows: 0  no arterioles injured;
was amplified using the Perkin-Elmer thermal cycler
0.5  	15%; 1  15% to 30%; 1.5  31% to 45%; 2 
(Norwalk, CT, USA). Cycles used for PCR for both Flt-1
46% to 60%; 2.5  61% to 75%; and 3  
75%. and KDR/Flk-1 were 94C, 5 minutes (once); 94C, 1
minute, 58C, 1 minute, and 72C, 1 minute (30 cycles);Northern blot analysis
and 72C, 5 minutes (once). PCR products were electro-
Renal tissue was finely minced with a razor blade on ice phoresed in 1% agarose gel and photographed under
then homogenized in TRIzol reagent (Gibco Brl, Grand ultraviolet light. The cDNA probes obtained were se-
Island, NY, USA). RNA extraction was performed per quenced and the correct sequences were confirmed. The
manufacturer’s protocol. After resuspension in Tris-ethyl- PCR products were cloned using the Original TA Clon-
enediaminetetraacetic acid (EDTA) buffer, RNA con- ing kit (Invitrogen, Carlsbad, CA, USA).
centrations were determined using spectrophotometric
readings at absorbance260. RNA, 30 g, were electropho- VEGF Western blot analysis
resed in each lane in 0.9% agarose gels containing 2.2 Frozen (70C) kidney tissue sections embedded in
mol/L formaldehyde and 0.2 mol/L 3-[N-morpholino]- Tissue-Tek O.C.T. (Miles, Inc., Diagnostics Division,
propanesulfonic acid (Mops) (pH 7.0) and transferred Elkhart, IN, USA) were processed for protein extraction
to a nylon membrane (ICN Biomedicals, Costa Mesa, CA, as previously described [5]. Equal amounts of protein
USA) overnight by capillary blotting. Nucleic acids were were resolved on 15% SDS-PAGE gel (Bio-Rad, Rich-
crosslinked by ultraviolet irradiation (Stratagene, La Jolla, mond, CA, USA), then electroblotted to nitrocellulose
CA, USA). The membranes were prehybridized for 2 hours membranes (Bio-Rad). After blocking the membranes
at 42C with 50% formamide, 10% Denhardt’s solution, for 1 hour with tris-buffered saline–tween 20 (TBS-T),
0.1% sodium dodecyl sulfate (SDS), 5 standard saline they were incubated with goat polyclonal VEGF anti-
citrate (SSC), and 200 g/mL denatured salmon sperm body (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
DNA. They were hybridized at 42C for 18 hours with (1:100 dilution). The secondary antibody was antigoat
cDNA probes labeled with 32P-dCTP by random oligo- (Santa Cruz) (1:2000 dilution) conjugated with alkaline
nucleotide priming (Boehringer Mannheim). Blots were phosphatase. The detection of signal employed a colori-
washed in 2 SSC, 0.1% SDS at room temperature for metric subtraction kit (Zymed, San Francisco, CA, USA).
15 minutes and in 0.1 SSC, 0.1% SDS at 50C for 15
VEGF immunohistochemical stainingminutes. Films were exposed at70C for different time
periods to ensure linearity of densitometric values and Four-micron sections of formalin-fixed, paraffin-embed-
exposure time. Autoradiographs were scanned on an im- ded tissue were cleared with xylene and hydrated using
decreasing concentrations of ethanol. The primary anti-aging densitometer (GS-700, Bio-Rad Laboratories, Her-
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Table 1. Physiologic changes in the experimental groups
Blood pressure Creatinine clearance Urinary nitric oxide CsA blood trough level
mm Hg mL/min/100 g lmol/24 h ng/mL
7 days
CsA 1304 0.330.03 7.81.0 1279207
CsA  L-NAME 1363 0.270.02a 5.00.7a 133165
CsA  l-Arg 1325 0.350.01 12.21.4a,b 1348124
Vehicle 1214 0.420.01 7.91.0 0
Vehicle  L-NAME 1373 0.370.02 5.31.0 0
Vehicle  l-Arg 1384 0.460.03 12.91.2a 0
28 days
CsA 1256 0.260.02a 6.91.2 2422214
CsA  L-NAME 1243 0.160.00a,b 4.10.7a,b 1923498
CsA  l-Arg 1272 0.380.06a,b 13.62.3a,b 201456
Vehicle 1295 0.410.02 8.51.2 0
Vehicle  L-NAME 1397 0.430.02 5.40.9a 0
Vehicle  l-Arg 1332 0.440.04 13.11.9a 0
Abbreviations are: CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl ester; l-Arg, l-arginine. Data are meanSEM of five to six animals.
aP 	 0.05 vs. vehicle; bP 	 0.05 vs. CsA
Table 2. Histologic semiquantitative scoringbody was a rabbit polyclonal antibody to human VEGF
(Santa Cruz). Staining for VEGF was performed in three Tubulointerstitial
fibrosis Arteriolopathyrepresentative animals from each group sacrificed at 28
7 days 28 days 7 days 28 daysdays. Control experiments included omission of either
the primary or secondary antibody. All sections for CsA 0.10.1 2.10.3a 0.10.1 1.50.7a
CsA  L-NAME 0.20.1 2.80.3a 0.30.2 1.80.6aVEGF staining were subjected to antigen retrieval using
CsA  l-Arg 0.00.0 0.90.2b 0.10.1 1.00.2bimmersion in a 0.1 mol/L citrate buffer (pH 6.0), followed
Vehicle 0.00.0 0.10.1 0.00.0 0.10.1
by heating in an electrical pressure cooker for 3 minutes Vehicle  L-NAME 0.00.0 0.10.1 0.00.0 0.10.1
Vehicle  l-Arg 0.00.0 0.10.1 0.00.0 0.10.1(total time, 30 minutes). All steps were carried out at
Abbreviations are: CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl37C. The primary VEGF antibody was applied over-
ester; l-Arg, l-arginine. Data are meanSEM of five to six animals.night at a dilution of 1:100. This was sequentially fol- aP 	 0.05 vs. vehicle; bP 	 0.05 vs. CsA
lowed by incubation for 30 minutes with a secondary
antirabbit IgG antibody (Sigma) at a 1:300 dilution and
streptavidin peroxidase-conjugated (Dako, Carpenteria,
CA, USA), with color development using diaminobenzi- Moreover, L-NAME administration significantly worsened
GFR in CsA-treated groups, with the difference achiev-dine (Dako) for 5 minutes.
ing statistical significance at 28 days. On the other hand,
Statistical analysis l-Arg treatment protected the animals treated with CsA
from impaired GFR but did not return the values to theResults are presented as mean standard error. Com-
parisons between groups were done by analysis of vari- vehicle group levels. The effect of nitric modulation on
GFR was not observed in the vehicle-treated groups.ance (Kruskal-Wallis test followed by Tukey test). The
level of statistical significance was chosen as P 	 0.05. L-NAME administration resulted in a significantly lower
urinary nitric oxide excretion in CsA and vehicle-treated
groups. On the other hand, urinary nitric oxide excretion
RESULTS
was significantly increased with l-Arg in both groups.
Physiologic studies While CsA treatment lowered urinary nitric oxide excre-
tion compared to vehicle treatment, the difference didValues for systolic blood pressure, creatinine clear-
ance and CsA whole blood trough levels are summarized not achieve statistical significance.
in Table 1. Weight gain was progressive in all the groups
Histologic changes(data not shown) and there were no differences except
in the 28 days CsA  L-NAME group, which failed to When the extent of the histologic changes was graded
using a 0 to 3 semiquantitative score, most of the differ-gain as much weight (312 g  42 g, P 	 0.05 vs. CsA,
393 g  7 g). CsA blood levels were similar at the end ences were observed at 28 days (Table 2). Vehicle-
treated rats demonstrated normal kidney histology at 7of each treatment period. CsA-induced hypertension was
not observed and there were no significant differences and 28 days (Fig. 1A). By contrast, the kidneys of CsA-
treated rats developed a striped pattern of interstitialin blood pressure among all groups. CsA treatment sig-
nificantly decreased glomerular filtration rate (GFR). fibrosis and tubular atrophy mostly evident at 28 days
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Fig. 1. Histologic changes. Representative photomicrographs showing the renal cortex of a salt-depleted rat given cyclosporine (CsA), 7.5 mg/
kg/day (A ), CsA  N-nitro-l-arginine-methyl ester (L-NAME) (B ), CsA  l-arginine (l-Arg) (C ), or vehicle (placebo) (D ) for 28 days. Vehicle-
treated rats display normal kidney histology (D). In rats treated with CsA, extensive interstitial fibrosis and tubular atrophy (A) are seen. When
both CsA and l-Arg are given in combination, these changes are markedly reduced (C). In contrast, when both CsA and L-NAME are given in
combination, the interstitial fibrosis and tubular atrophy are much more extensive (B). (Trichrome, original magnification 100).

(Fig. 1B). While L-NAME worsened the tubulointersti- junction and outer medullary areas. CsA-treated rats
tial changes in CsA-treated rats (Fig. 1C), l-Arg treat- exhibited a strong and diffuse cytoplasmic staining for
ment resulted in significantly less severe (P 	 0.05 vs. VEGF. This was in sharp contrast with vehicle-treated
CsA) interstitial fibrosis and tubular atrophy (Fig. 1D). rats that showed only focal, faint and nonspecific cyto-
The kidneys of CsA-treated rats also showed prominent plasmic staining for VEGF in tubular epithelial cells.
vascular lesions characterized by hypertrophied smooth Moreover, treatment of CsA rats with L-NAME in-
muscle cells of the afferent arterioles with characteristic creased the intensity of VEGF staining in tubular epithe-
granular eosinophilic transformation. Although arte- lial cells. On the other hand, the VEGF staining in the
riolopathy was substantially worse in animals treated kidneys of CsA  l-Arg group of rats was focal and
with L-NAME, the changes did not attain statistical sig- faint, similar to vehicle-treated rats.
nificance. On the other hand, l-Arg treatment signifi-
cantly improved (P 	 0.05) CsA-associated arteriolopa- Flt-1 and KDR/Flk-1 receptors expressions
thy. Treatment of vehicle rats with L-NAME or l-Arg The mRNA expressions of the Flt-1 and KDR/Flk-1
had no effect on kidney histology. receptors are shown in Figures 5 to 7. Flt-1 receptor
expression was not statistically different between theVEGF expression
groups and was independent of nitric oxide modulation
VEGF mRNA expression was significantly up-regu- (Figs. 5 and 7). On the other hand, the behavior of KDR/
lated in CsA- versus vehicle-treated rats (Figs. 2 and 7). Flk-1 was somewhat different and paralleled the changes
This effect was seen at 7 days (P 	 0.05 versus vehicle)
seen with VEGF expression (Figs. 6 and 7). CsA treat-
and progressed at 28 days (P 	 0.05 versus vehicle).
ment increased KDR/Flk-1 mRNA expression; theNitric oxide modulation did not affect VEGF mRNA
changes were seen early at 7 days (P 	 0.05 versusexpression in the vehicle-treated rats. In the CsA groups,
vehicle) and progressively increased at 28 days (P	 0.05L-NAME was associated with increased VEGF mRNA
versus vehicle). Similar to VEGF, L-NAME treatmentat 7 and 28 days. In contrast, treatment with l-Arg re-
resulted in a higher KDR/Flk-1 receptor expression;duced VEGF mRNA in the CsA groups at 7 and 28 days
however, this was not observed until 28 days (P 	 0.05to the vehicle levels (P 	 0.01 versus CsA). The protein
versus vehicle and CsA). The opposite trend was seenexpression of VEGF followed the same trend as its
with l-Arg treatment where KDR/Flk-1 mRNA expres-mRNA expression (Fig. 3). However, VEGF protein
sion declined to levels similar to vehicle at 7 days (P 	expression in the CsA-treated rats was delayed com-
0.05 versus CsA) and further lower than vehicle at 28pared to its mRNA expression and did not become sig-
days (P 	 0.05 versus vehicle and CsA). Nitric oxidenificantly higher than vehicle-treated groups until 28 days
modulation had no effect on the receptors’ expression(P 	 0.05). Treatment with L-NAME resulted in a sig-
in vehicle-treated rats, an effect similar to that observednificantly higher VEGF protein expression as early as 7
with VEGF.days with the changes persisting at 28 days (P 	 0.05
versus CsA and vehicle). On the other hand, l-Arg treat-
ment in the CsA groups decreased VEGF protein ex-
DISCUSSIONpression to values lower than the vehicle groups (P 	
Several studies have suggested that nitric oxide is in-0.05 versus vehicle and CsA).
volved in the hemodynamic alterations encountered withThe immunohistochemical staining for VEGF at 28
days (Fig. 4) was mostly present in the corticomedullary CsA treatment [25]. CsA-induced acute renal dysfunc-

Fig. 4. Immunohistochemical staining for vascular endothelial growth factor (VEGF). Representative photomicrographs of kidney sections from
cyclosporine (CsA)- (A ), CsA  N-nitro-l-arginine (L-NAME)- (B ), CsA  l-arginine (l-Arg)- (C ) and vehicle-treated (D ) rats for 28 days
stained with an antibody to VEGF. CsA-treated rats exhibited a strong and diffuse tubular epithelial staining (A). In contrast, the staining for
vehicle-treated rats was faint, focal and nonspecific (D). Treatment with L-NAME intensified (B) while treatment with l-Arg of CsA rats greatly
reduces the intensity of VEGF staining (C). Original magnification 400.
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nitric oxide augmentation is associated with a decrease in
VEGF expression while nitric oxide blockade increased
VEGF expression in chronic CsA nephrotoxicity. How-
ever, it is important to note that the changes in VEGF
expression with nitric oxide modulation could be the
indirect result of the changes induced by nitric oxide on
renal hemodynamics and structure rather than a direct
effect by nitric oxide. Exogenous VEGF administration
was previously shown to have a blood pressure–lowering
effect in rats on high-salt diet receiving CsA [29]. How-
ever, while affecting VEGF expression, nitric oxide mod-
ulation did not result in changes in blood pressure read-
ings in this model.
The vasoconstricting effect of CsA on the renal vascu-
lature induces hypoxia. Hypoxia is involved in causing
acute CsA nephrotoxicity and is also thought to play a
role in the pathogenesis of chronic CsA nephrotoxicity
[1]. Since hypoxia is a potent inducer of VEGF, it may
explain partly the increased VEGF expression in this
model. In addition, it is postulated that VEGF is involved
in maintaining endothelial integrity [16]. Since CsA can
be injurious to endothelial cells, VEGF may become
up-regulated in an attempt to repair and maintain the
damaged endothelium. For example, VEGF administra-
tion was shown to accelerate the restitution of endothe-
lial integrity in balloon-injured arteries [30]. In addition,
treatment with VEGF reduces CsA-induced hyperten-
sive responses in rats on a high-salt diet. The hypoxia-Fig. 2. Northern blot expression of vascular endothelial growth factor
(VEGF) mRNA. Total RNA was isolated from whole cortex at 7 and induced transcription of VEGF mRNA is apparently
28 days and hybridized with a cDNA probe to VEGF. Results of mediated by the binding of hypoxia-inducible factordensitometric analysis after correcting for glyceraldehyde-3-phosphate
(HIF)-1 to an HIF-1 binding site in the VEGF promoterdehydrogenase (GAPDH) mRNA are shown (A ). Northern blot repre-
sentative is also shown (B ). Abbreviations are: VH, vehicle or placebo; [11]. Moreover, hypoxia is thought to increase VEGF
CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl ester; l-Arg, mRNA stability in addition to inducing its expressionl-arginine. *P 	 0.05 vs. vehicle; #P 	 0.05 vs. CsA.
[31]. It is interesting to note that the VEGF gene contains
a number of motifs in the 3untranslated region involved
in regulating mRNA stability [32].
There is also ample evidence to suggest that an in-tion was shown to improve with l-Arg administration
and to worsen with nitric oxide blockade [26, 27]. In creased VEGF expression in renal diseases is associated
with fibrosis. We have shown that the fibrosis of CsAchronic CsA nephrotoxicity, l-Arg administration has a
protective role by limiting tubulointerstitial fibrosis and nephrotoxicity is associated with an increase in endoge-
nous VEGF expression, mostly in the tubulointerstitiumtubular atrophy [24, 28]. These changes were associated
with a decrease in TGF-1, plasminogen activator inhibi- [5]. A similar finding was observed in chronic renal allo-
graft rejection, a renal disease with histologic similaritiestor-1, and ECM proteins [24]. Administration of l-Arg
is also beneficial in decreasing fibrosis in a number of to chronic CsA nephrotoxicity [20]. Moreover, VEGF
expression is enhanced in mesangial cells in the earlyrenal diseases [22, 23]. Thus, it is clear that nitric oxide
plays a direct role in modulating fibrosis. In addition, we stages of glomerulonephritis. A study of VEGF expres-
sion in renal diseases noted that patients with chronichave previously shown that the expression of VEGF
and receptors Flt-1 and KDR/Flk-1 was up-regulated in renal disease had markedly up-regulated VEGF expres-
sion in the interstitium, but that the signals were reducedchronic CsA nephrotoxicity [5]. The changes were seen
only in rats on low-salt diet in which nephrotoxicity de- in globally sclerosed glomeruli [33]. This is consistent
with a temporal sequence in which VEGF expressionveloped and not in normal-salt diet rats that remained
disease free. This led to the suggestion that it is CsA precedes renal fibrosis and is then either down-regulated
or disrupted after the progression of fibrosis. Whethernephrotoxicity, and not merely CsA administration, that
is responsible for the enhanced VEGF expression. In VEGF contributes directly to ECM accumulation or
whether it is produced in response to fibrosis remainsthis study, we show for the first time that exogenous
Shihab et al: VEGF and receptors in cyclosporine nephrotoxicity 529
Fig. 3. VEGF protein expression by West-
ern blot. Protein was isolated from whole
cortex at 7 and 28 days and hybridized with a
goat polyclonal antimouse VEGF antibody.
Results of the densitometric analysis of
equal amounts of protein are shown (A ).
Western blot representative is also shown
(B ). Abbreviations are: VH, vehicle or pla-
cebo; CsA, cyclosporine; L-NAME, N-nitro-
l-arginine-methyl ester; l-Arg, l-arginine.
*P 	 0.05 vs. vehicle; #P 	 0.05 vs. CsA.
unclear. However, the expression of VEGF was shown [10–12]. Nitric oxide donors are capable of suppressing
the transcription of a reporter gene containing the VEGFto be induced by TGF- pathways [6, 7, 34–36] in several
hypoxic enhancer and the binding of the transcriptionalcell lines. More recently, a fragment within the VEGF
activator HIF-1 to the enhancer [10–12]. In a separatepromoter has been identified as a target for Smad pro-
study, sodium nitroprusside, a nitric oxide donor, wasteins, which are critical for transmitting TGF- signals
capable of inhibiting the activity of the VEGF promoterfrom the cell surface to the nucleus [37]. Thus, since
controlled by HIF-1 [41]. Moreover, in lungs exposed toTGF- is a potent fibrogenic cytokine that plays a major
chronic hypoxia, sodium nitroprusside decreased whilerole in chronic CsA nephrotoxicity, an increase in TGF-
L-NAME increased the expression of both VEGF andcould be contributing to the up-regulated VEGF expres-
receptors transcripts [9]. Nitric oxide donors inhibit pro-sion in this model [1–5]. In the remnant kidney model,
tein kinase C induced by VEGF by interfering with bind-exogenous VEGF administration was shown to reduce
ing of the transcription factor AP-1 [8]. In addition, cyclicfibrosis and to stabilize renal function [38]. Thus, it re-
guanosine monophosphate (cGMP) has a suppressive
mains unclear if VEGF is in fact a signaling molecule effect similar to nitric oxide on the hypoxic induction of
involved in enhancing fibrosis. More recently, VEGF was VEGF. Thus, it is thought that nitric oxide can regulate
shown to activate MAP kinase and to enhance collagen cGMP levels, which, in turn, modulate VEGF expression
synthesis in human mesangial cells [39]. On the other in vascular smooth muscle and endothelial cells [11, 12].
hand, VEGF was reported to induce interstitial collagen- It is also possible that a cGMP-dependent protein kinase
ase in endothelial cells but not in fibroblasts [40]. Thus, pathway is involved. In fact, protein phosphorylation
both ECM synthesis and degradation may be regulated events were shown to occur following VEGF stimulation
by VEGF through contrasting actions on renal cells. of endothelial cells. Thus, the nitric oxide effects on a
Nitric oxide was previously reported to suppress the nitric oxide–dependent protein kinase and on VEGF
could co-exist.hypoxic induction of VEGF in vascular endothelial cells
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Fig. 5. Northern blot expression of Flt-1 mRNA. Total RNA was iso- Fig. 6. Northern blot expression of KDR/Flk-1 mRNA. Total RNA
lated from whole cortex at 7 and 28 days and hybridized with a cDNA was isolated from the whole cortex at 7 and 28 days and was hybridized
probe to Flt-1. Results of densitometric analysis are shown (A ). North- with a cDNA probe to KDR/Flk-1. Results of densitometric analysis are
ern blot representative is also shown (B ). Abbreviations are: VH, vehi- shown (A). Northern blot representative is also shown (B). Abbreviations
cle or placebo; CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl are: VH, vehicle or placebo; CsA, cyclosporine; L-NAME, N-nitro-l-arginine-
ester; l-Arg, l-arginine. methyl ester; l-Arg, l-arginine. *P 	 0.05 vs. vehicle; #P 	 0.05 vs. CsA.
There are many reports that implicate angiotensin II KDR/Flk-1 was similar to VEGF, while the behavior of
Flt-1 was independent of nitric oxide modulation. Based(Ang II) as a trigger for nitric oxide production and that
nitric oxide is capable of antagonizing Ang II-induced on these findings, we conclude that VEGF probably ex-
erted its biological effect in this model via KDR/Flk-1.vasoconstriction in the kidney [42–44]. In addition, Ang
II and nitric oxide have opposing effects on the produc- However, we did not investigate whether the effect of
nitric oxide on receptors’ expression occurred via VEGFtion of ECM proteins and on the progression of chronic
renal diseases. Ang II is thought to exhibit profibrotic or was independent of VEGF. These two receptors dis-
play differences in function; for example, KDR/Flk-1-actions, at least partly, through TGF-. Since both Ang
II and TGF- inhibit cytokine-induced nitric oxide pro- expressing cells show changes in morphology, chemo-
taxis, and mitogenicity upon VEGF stimulation, whereasduction, this was postulated to explain the beneficial
effect that nitric oxide has on fibrosis in this model Flt-1-expressing cells lack such response [6, 7, 15]. Gene
knockout experiments also suggest differences in vascu-[24, 45]. Previous reports have also demonstrated that
Ang II is a potent stimulus for VEGF in vascular smooth lar development [6, 7]. It is thought that Flt-1 is not
a signal receptor, but rather a “decoy” receptor thatmuscle, in cardiac and retinal endothelial, and in mesan-
gial cells [42–44]. In this same model, we have previously negatively regulates VEGF by sequestering it and ren-
dering it less available to KDR/Flk-1 [46]. However,shown that Ang II blockade decreases VEGF expression
[45]. Thus, another explanation for the effect of nitric subsequent studies indicated that Flt-1 interacts with
some signal-transducing proteins [15]. Nevertheless,oxide modulation on VEGF expression could be the
opposing effect that nitric oxide has on Ang II in this most studies support the hypothesis that interaction with
KDR/Flk-1 is a critical requirement to induce the fullmodel.
We also investigated the effect of nitric oxide modula- spectrum of VEGF biological responses. In addition, it
used to be believed that VEGF receptors were restrictedtion on VEGF receptors’ expression. The expression of
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Fig. 7. Time course for the expression of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR/Flk-1. Abbreviations are:
VH, vehicle or placebo; CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl ester; l-Arg, l-arginine. N  five to six animals/group.
to the endothelium and that VEGF exerts its activity in is capable of decreasing monocytic attraction, thereby
aborting a self-perpetuating loop of myofibroblast prolif-an autocrine method. However, recent findings con-
firmed the presence of VEGF receptors on nonendothe- eration and interstitial fibrosis.
The results reported herein raise some intriguing ques-lial cells and suggested that VEGF acts also in a paracrine
method [47]. tions. Since VEGF is a potent endothelial cell mitogen,
it is possible that VEGF production is a compensatoryIt is also postulated that some of the beneficial effects
of nitric oxide administration on fibrosis are related not mechanism directed at replacing the damaged endothe-
lium caused by CsA. In addition, it is possible that VEGFonly to its effect on TGF- expression but may be the
result of decreasing the amount of macrophage infiltra- plays a role, either independently or through nitric oxide,
in CsA-induced fibrosis. This may be related either di-tion [22]. It is important to note that our CsA model
displays features of a mononuclear infiltrate that occurs rectly through its effect on matrix remodeling or indi-
rectly through its chemotactic effect on monocytes. Moreearly and precedes interstitial fibrosis. Moreover, we
know that VEGF is chemotactic for macrophages and studies are needed to define the interactions between
nitric oxide, Ang II, TGF-, and VEGF and to delineateis increased in conditions associated with macrophage
infiltration. In human chronic rejection, VEGF-positive their individual roles in this model. In addition, studies
are needed to determine the clinical consequences ofcells in the interstitium colocalized with macrophages
[20]. Thus, it is possible that l-Arg, by decreasing VEGF, decreased VEGF with nitric oxide modulation.
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